Study Finds RIV4 Is Well Tolerated, Demonstrates Noninferior Immune Responses In Pediatric, Adult Populations

Infectious Disease Advisor (7/21, Basilio) reports, “The quadrivalent recombinant influenza vaccine (RIV4) is well tolerated and demonstrates noninferior immune responses in pediatric and adult populations, according to study findings.” The researchers said, “The findings from this study could expand vaccine options for children, offering alternatives to egg-based formulations.” The findings were published in The Lancet Infectious Diseases.